Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Stock Short Interest Report for September

by · The Markets Daily

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ – Get Free Report) saw a significant growth in short interest in September. As of September 30th, there was short interest totaling 164,782 shares, a growth of 95.6% from the September 15th total of 84,256 shares. Currently, 2.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 2,143,151 shares, the short-interest ratio is currently 0.1 days.

Analyst Ratings Changes

A number of brokerages recently weighed in on CELZ. Roth Capital reissued a “buy” rating on shares of Creative Medical Technology in a research note on Thursday, August 20th. Wall Street Zen upgraded Creative Medical Technology from a “sell” rating to a “hold” rating in a report on Saturday, September 12th. Finally, Weiss Ratings lowered shares of Creative Medical Technology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 24th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold”.

Check Out Our Latest Research Report on Creative Medical Technology

Creative Medical Technology Price Performance

Creative Medical Technology stock traded down $0.01 during midday trading on Friday, reaching $0.81. The stock had a trading volume of 9,698 shares, compared to its average volume of 3,228,677. The firm’s fifty day simple moving average is $1.04 and its two-hundred day simple moving average is $1.52. Creative Medical Technology has a twelve month low of $0.62 and a twelve month high of $6.25. The firm has a market cap of $5.30 million, a price-to-earnings ratio of -0.39 and a beta of 2.06.

Creative Medical Technology (NASDAQ:CELZ – Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.02). As a group, sell-side analysts predict that Creative Medical Technology will post -1.18 EPS for the current fiscal year.

About Creative Medical Technology

(Get Free Report)

Creative Medical Technology Holdings, Inc is a clinical-stage biotechnology company focused on developing regenerative medicine and cellular therapies. The company’s research uses adult stem cells and other cell-based approaches intended to address conditions with limited treatment options, including immune, neurological, metabolic and urological disorders.

Its development programs have included CaverStem, an autologous bone marrow-derived cell therapy platform being investigated for erectile dysfunction, as well as ImmCelz and NeuroCelz programs designed to explore cell-based treatments for immune-related and neurological conditions.

Featured Articles